提示: 手机请竖屏浏览!

阿替利珠单抗联合贝伐珠单抗——肝癌治疗的里程碑
Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer


Robin K. Kelley ... 肿瘤 • 2020.05.14
相关阅读
• 贝伐珠单抗联合阿替利珠单抗治疗晚期肝细胞癌 • 阿替利珠单抗联合贝伐珠单抗治疗不可切除的肝细胞癌 • 肝细胞癌

10多年前,索拉非尼成为第一个在晚期肝细胞癌治疗中取得显著生存获益的全身性疗法1。自那时以来,还没有出现疗效超过索拉非尼的一线治疗,直到2020年5月14日出版的《新英格兰医学杂志》发表Finn及其同事关于阿替利珠单抗联合贝伐珠单抗的治疗方案2。与索拉非尼相比,阿替利珠单抗(一种程序性死亡受体配体1[PD-L1]抑制剂)+贝伐珠单抗(一种靶向血管内皮生长因子的单克隆抗体)联合治疗显著改善了总生存和无进展生存以及患者报告的结局。

这些数据意义重大,因为对于肝细胞癌这种极具挑战性的癌症,这些数据不仅确立了第一种生存结局优于索拉非尼的疗法,而且确立了第一种成功的联合治疗方案,确立了第一项得到阳性结果的随机、3期免疫检查点抑制试验。尽管阿替利珠单抗-贝伐珠单抗成为了不断扩大的肝细胞癌治疗策略中的新成员,Finn等试验数据的几个方面仍值得进一步研究,包括出血风险大小和对更广泛患者人群的疗效。此外,我们还应进行亚组分析,以识别其他免疫检查点抑制剂试验中的候选生物标志物,并应评价患者结局是由于两种单抗的协同效应还是叠加效应,因为这一问题可能会决定是使用联合还是序贯用药策略。





作者信息

Robin K. Kelley, M.D.
From the Division of Hematology–Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco.

 

参考文献

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

3. Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012;17:1063-72.

4. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8.

5. Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase II open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the firstline treatment of patients with advanced hepatocellular carcinoma. Oncology 2018;94:329-39.

6. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15.

7. Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Presented at the 2019 Congress of the European Society of Medical Oncology, Barcelona, September 27–October 1, 2019. abstract.

8. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.

9. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.

10. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 2017;153:812-26.

11. Lee M, Ryoo B-Y, Hsu C, et al. Randomised efficacy and safety results for atezolizumab (ATEZO) + bevacizumab (BEV) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Presented at the 2019 Congress of the European Society of Medical Oncology, Barcelona, September 27– October 1, 2019. abstract.

12. Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res 2019;25:5449-57.

13. Food and Drug Administration. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. March 10, 2020 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma).

服务条款 | 隐私政策 | 联系我们